Hydroxychloroquine
Treatment for Lupus
Typical Dosage: 200-400 mg daily
Effectiveness
85%
Safety Score
65%
Clinical Trials
38
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
200-400 mg daily
Time to Effect
3-6 months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Harm (NNH)
2500(Treat 2500 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$1,167
Cost per Remission
$2,800
Hydroxychloroquine Outcomes
for Lupus
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+60%
Remission Rate
+25%
Common Side Effects
Nausea, diarrhea
+15%
Headache
+10%
Skin rash
+7%
Retinal toxicity (rare)
+0.5%
Sources:
Active Clinical Trials
3 active trials recruiting for Hydroxychloroquine in Lupus
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
NCT05799378RECRUITINGPHASE3
330 participants
INTERVENTIONAL
Los Angeles, United States +9 more
Started: Jun 27, 2024
Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
NCT05666336RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Changsha, China
Started: Dec 31, 2022
Chinese Rheumatism Biobank(CRB)
NCT06887517RECRUITING
300 participants
OBSERVATIONAL
Beijing, China
Started: Feb 10, 2025
Completed Clinical Trials
12 completed trials for Hydroxychloroquine in Lupus
Lupus and Observance
NCT03019926COMPLETED
200 participants
OBSERVATIONAL
Fort-de-France, France
Started: Jan 19, 2017
Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus
NCT02842814COMPLETEDNA
333 participants
INTERVENTIONAL
Hefei, China +4 more
Started: Oct 1, 2016
Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion
NCT01551069COMPLETEDPHASE3
103 participants
INTERVENTIONAL
Bunkyō City, Japan +21 more
Started: Mar 1, 2012
The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS
NCT00413361COMPLETEDPHASE4
543 participants
INTERVENTIONAL
Paris, France +1 more
Started: Jun 1, 2007
Study of Anti-Malarials in Incomplete Lupus Erythematosus
NCT03030118COMPLETEDPHASE2
187 participants
INTERVENTIONAL
Los Angeles, United States +6 more
Started: Dec 28, 2017
Preventive Approach to Congenital Heart Block With Hydroxychloroquine
NCT01379573COMPLETEDPHASE2
74 participants
INTERVENTIONAL
New York, United States
Started: Jan 1, 2011
Clarifying Misbeliefs About Hydroxychloroquine: Developing a Decision Aid for Patients With Lupus
NCT05922722COMPLETED
200 participants
OBSERVATIONAL
Madison, United States
Started: Feb 15, 2024
Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis
NCT02756546COMPLETEDPHASE1, PHASE2
100 participants
INTERVENTIONAL
Started: Sep 1, 2014
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
NCT03122431COMPLETEDPHASE4
93 participants
INTERVENTIONAL
São Paulo, Brazil
Started: Jun 5, 2017
Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
NCT06161363COMPLETED
102 participants
OBSERVATIONAL
Toulouse, France
Started: Nov 27, 2023
Individual Patient Exposure and Response in Pediatric Lupus
NCT04358302COMPLETEDNA
26 participants
INTERVENTIONAL
Durham, United States
Started: Sep 28, 2020
Covid-19 in Lupus Patients
NCT04355702COMPLETED
130 participants
OBSERVATIONAL
Montpellier, France
Started: Mar 1, 2020
Showing 20 of 38 total trials